Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.

Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC.

Oncotarget. 2017 Apr 18;8(16):26169-26184. doi: 10.18632/oncotarget.15410.

2.

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Creaney J, Dick IM, Leon JS, Robinson BW.

Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):103-117.

3.

Elevated levels of ribosomal proteins eL36 and eL42 control expression of Hsp90 in rhabdomyosarcoma.

Shaikho S, Dobson CC, Naing T, Samanfar B, Moteshareie H, Hajikarimloo M, Golshani A, Holcik M.

Translation (Austin). 2016 Oct 4;4(2):e1244395. doi: 10.1080/21690731.2016.1244395. eCollection 2016.

4.

Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.

Webber PJ, Park C, Qui M, Ramalingam SS, Khuri FR, Fu H, Du Y.

Oncoscience. 2015 Sep 15;2(9):765-776. eCollection 2015.

5.

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Bononi A, Napolitano A, Pass HI, Yang H, Carbone M.

Expert Rev Respir Med. 2015 Oct;9(5):633-54. doi: 10.1586/17476348.2015.1081066. Epub 2015 Aug 26. Review.

6.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.

Br J Cancer. 2014 May 13;110(10):2479-88. doi: 10.1038/bjc.2014.220. Epub 2014 Apr 24.

7.

Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.

Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ.

Cell Death Dis. 2013 Mar 28;4:e566. doi: 10.1038/cddis.2013.101.

8.
9.

Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Favoni RE, Daga A, Malatesta P, Florio T.

Br J Pharmacol. 2012 May;166(2):532-53. doi: 10.1111/j.1476-5381.2012.01873.x. Review.

10.

High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.

Lyman SK, Crawley SC, Gong R, Adamkewicz JI, McGrath G, Chew JY, Choi J, Holst CR, Goon LH, Detmer SA, Vaclavikova J, Gerritsen ME, Blake RA.

PLoS One. 2011 Mar 7;6(3):e17692. doi: 10.1371/journal.pone.0017692. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/73d83e95-8f14-48ed-bb67-2310a33e4ecc.

11.

Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.

Wang G, Ye Y, Yang X, Liao H, Zhao C, Liang S.

PLoS One. 2011 Jan 21;6(1):e14573. doi: 10.1371/journal.pone.0014573.

12.

Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA.

Neoplasia. 2011 Jan;13(1):12-22.

13.
14.

17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Napper JM, Sollars VE.

Leuk Res. 2010 Nov;34(11):1493-500. doi: 10.1016/j.leukres.2010.05.024. Epub 2010 Jun 19.

15.

The role of protein synthesis in cell cycling and cancer.

White-Gilbertson S, Kurtz DT, Voelkel-Johnson C.

Mol Oncol. 2009 Dec;3(5-6):402-8. doi: 10.1016/j.molonc.2009.05.003. Epub 2009 Jun 11. Review.

16.

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.

Watanabe G, Behrns KE, Kim JS, Kim RD.

Cancer Chemother Pharmacol. 2009 Aug;64(3):433-43. doi: 10.1007/s00280-008-0888-2. Epub 2008 Dec 12.

Supplemental Content

Support Center